Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,506 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C.
Moritou Y, Ikeda F, Iwasaki Y, Baba N, Takaguchi K, Senoh T, Nagano T, Takeuchi Y, Yasunaka T, Ohnishi H, Miyake Y, Takaki A, Nouso K, Yamamoto K. Moritou Y, et al. Among authors: iwasaki y. Springerplus. 2013 Jun 1;2(1):251. doi: 10.1186/2193-1801-2-251. Print 2013 Dec. Springerplus. 2013. PMID: 23772356 Free PMC article.
Association of hepatic oxidative stress and iron dysregulation with HCC development after interferon therapy in chronic hepatitis C.
Nanba S, Ikeda F, Baba N, Takaguchi K, Senoh T, Nagano T, Seki H, Takeuchi Y, Moritou Y, Yasunaka T, Ohnishi H, Miyake Y, Takaki A, Nouso K, Iwasaki Y, Yamamoto K. Nanba S, et al. Among authors: iwasaki y. J Clin Pathol. 2016 Mar;69(3):226-33. doi: 10.1136/jclinpath-2015-203215. Epub 2015 Aug 19. J Clin Pathol. 2016. PMID: 26290259 Clinical Trial.
Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C.
Matsushita H, Ikeda F, Iwasaki Y, Seki H, Nanba S, Takeuchi Y, Moritou Y, Yasunaka T, Onishi H, Miyake Y, Takaki A, Nouso K, Yamamoto K. Matsushita H, et al. Among authors: iwasaki y. J Gastroenterol Hepatol. 2014 Feb;29(2):337-43. doi: 10.1111/jgh.12337. J Gastroenterol Hepatol. 2014. PMID: 23869873 Free article.
Impact of comorbid hepatic steatosis on treatment of chronic hepatitis C in Japanese patients and the relationship with genetic polymorphism of IL28B, PNPLA3 and LDL receptor.
Moritou Y, Ikeda F, Iwasaki Y, Baba N, Takaguchi K, Senoh T, Nagano T, Takeuchi Y, Yasunaka T, Ohnishi H, Miyake Y, Takaki A, Nouso K, Yamamoto K. Moritou Y, et al. Among authors: iwasaki y. Acta Med Okayama. 2014;68(1):17-22. doi: 10.18926/AMO/52139. Acta Med Okayama. 2014. PMID: 24553484 Free article.
The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis.
Takeuchi Y, Ikeda F, Moritou Y, Hagihara H, Yasunaka T, Kuwaki K, Miyake Y, Ohnishi H, Nakamura S, Shiraha H, Takaki A, Iwasaki Y, Nouso K, Yamamoto K. Takeuchi Y, et al. Among authors: iwasaki y. J Gastroenterol. 2013 Mar;48(3):405-12. doi: 10.1007/s00535-012-0647-3. Epub 2012 Aug 7. J Gastroenterol. 2013. PMID: 22869157 Free article.
Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance.
Ikeda F, Baba N, Takaguchi K, Kubota J, Miyoshi K, Fujioka S, Moritou Y, Takeuchi Y, Yasunaka T, Miyake Y, Takaki A, Iwasaki Y, Kobashi H, Yamamoto K. Ikeda F, et al. Among authors: iwasaki y. J Med Virol. 2012 Oct;84(10):1562-70. doi: 10.1002/jmv.23371. J Med Virol. 2012. PMID: 22930504
3,506 results